AzTrials
AzTrials

Dental ExtractionPhase 4NCT06793358

Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

A Phase 4 study testing fentanyl and Remimazolam in people with Dental Extraction, run by Indiana University at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if a combination of the two established sedation drugs remimazolam and fentanyl, can put the subject to sleep during a scheduled extraction procedure. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dental Extraction
What is being tested?
fentanyl and Remimazolam
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
31 Jul 2025to 27 Feb 2026
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Willing to read and sign the IRB (Institutional Review Board) approved informed consent document.
  • Patients 18 years of age and older on the day of the surgery
  • Healthy patients (ASA Physical Status class of 1 or 2)
  • Dental treatment consists of planned extractions expected to be completed in 30 minutes or less using IV moderate (procedural) sedation.

Who cannot join

  • List the criteria:
  • Allergy or negative history with either of the planned sedative medications (remimazolam, fentanyl) or local anesthetics to be used for dental extractions.
  • Previous negative history with the use of IV sedation medications
  • Use of opioid-containing analgesics within 24 hours of surgery
  • BMI >30 kg/m2
  • Patients with multiple or poorly controlled medical comorbidities (i.e., hypertension, COPD (chronic obstructive pulmonary disease), heart failure, asthma, diabetes).
  • Consumption within the last 24 hours of alcohol, illicit (marijuana, cocaine, etc.), opioid-containing, or other analgesic drugs.
  • Other contraindications to procedural/moderate sedation (i.e., concurrent illness, failure to follow NPO (nil per os) instructions, lack of escort)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Indiana University School of Dentistry (IUSD)

    Indianapolis, Indiana, 46202

Other trials in United States

About this study

The goal of this clinical trial is to learn if a combination of the two established sedation drugs remimazolam and fentanyl, can put the subject to sleep during a scheduled extraction procedure. The combined use of these drugs has been used in other studies involving IV sedation when the procedure is scheduled for 30 minutes or less. However, the combined use of the IV sedation drugs has not been used in a dental extraction procedure before.

The main questions it aims to answer are:

Read more
  1. Can the combined drugs effectively put the patient to sleep during the procedure
  2. How quickly will they come out of the sedation after the procedure

Participants will:

  1. Receive the combined drugs during a scheduled extraction procedure anticipated to take less than 30 minutes
  2. Answer survey questions related to their study experience after the extraction visit (in person) and again about 24 hours after the visit (by telephone).
Read the detailed description

Primary Objective The Primary objective of this study is to determine if the combination of remimazolam and fentanyl for IV procedural sedation is effective for completion of the planned surgical procedure (a composite of MOAA/S scores of 2-4, extraction of indicated teeth, no need for rescue medications [propofol, flumazenil]).

Secondary Objective Secondary objectives include determination of the speed of emergence and recovery from sedation as calculated by the total anesthesia time, total surgery time, time from end of surgery to emergence and fitness for discharge (modified Aldrete score ≥9, minimal/no PONV, pain controlled).

Tertiary/Exploratory/Correlative Objectives Other measured data will include changes in blood pressure and heart rate (+/- 20% of baseline); emergent/urgent use of vasoactive agents; changes in ventilation/oxygenation (hypoxemia, SpO2 <90%; rescue ventilation), MOAA/S scores <2, and other rare sedation complications (PONV, anaphylaxis, etc.).

Study Design This will be a single arm, single site, unblinded clinical trial using two marketed intravenous sedation drugs (remimazolam and fentanyl) to determine whether this drug combination is effective for dental extractions under procedural sedation.

Neither the study team member administering the study drugs, nor the participant will be blinded to the sedation drug they are receiving. Blinding is not necessary at this time since the study is a single-arm design.

Written informed consent will be obtained prior to any study procedures being performed.

Enrollment/Randomization Potential subjects will be patients who are scheduled for dental extractions under sedation in the IUSD Oral Surgery Clinic at IU Health University Hospital. Recruitment will occur chairside during the consultation appointment or at the extraction appointment, and up to 40 participants will receive remimazolam and fentanyl for procedural sedation as the IV sedatives for their planned dental extractions.

Study Procedures

Following the consenting procedure, the following will be performed:

  1. The patient will be weighed preoperatively (recorded in kg) and confirmation of adherence to NPO instructions (nothing by mouth) and presence of an escort will occur as per usual. The patient will then be escorted and seated in the dental operatory.
  2. Inclusion/Exclusion criteria will be reviewed to confirm eligibility.
  3. A dental exam and review of radiographs, collected as standard of care, will be performed along with confirmation of planned extractions.
  4. Preparation of the study drugs will occur in the standard, sterile fashion.
  5. Upon arrival to the dental operatory, standard anesthesia monitors (ECG, pulse oximetry, noninvasive BP cuff, nasal capnography, precordial stethoscope) will be placed. Supplemental oxygen at 4 L/min will be supplied via nasal cannula with CO2- carbon dioxide (capnography) monitoring capabilities.
  6. Preoperative vital signs (BP, HR (heart rate), RR (respiratory rate), room air SpO2) will be obtained after which an IV catheter will be placed in a suitable hand or antecubital vein in order to administer IV fluids (normal saline) and medications. Timing of the successful IV catheter placement will be recorded (anesthesia start time)
  7. Study drugs will be administered by a qualified study team member with notation of the time study drug administration began documented along with the dose.
  8. Study drug dosing will follow the same dosing protocol as documented in the initial Phase 3 trials. IV boluses of remimazolam (5 mg initially/2.5 mg additional boluses ≥2 min apart) and fentanyl (25-50 mcg initially/25 mcg additional boluses every 5-10 minutes; up to 100 mcg total) will be administered and titrated to desired procedural sedation level (MOAA/S: 2-4).
  9. Upon confirming targeted sedation depth has been achieved, the vital signs will be reassessed. A rubber bite block will then be placed intraorally, and the operating surgeon will administer local anesthetic solution (2% lidocaine with 1:100,000 epinephrine) as per usual. Local anesthetic total volumes will be documented along with the technique. Local anesthetics used are standard of care in any extraction procedure.
  10. Vital signs will be re-assessed 3 minutes after completing the local anesthetic injections and re-assessed every 5 minutes thereafter.
  11. The dental extractions will then be completed as per the departmental standard of care. Time of commencement of the extractions (surgery start time) will be recorded. The procedure will be observed by a study team member who will document any unusual occurrences that might be related to the study drug.
  12. Time of completion of the extractions (surgery end time) will be recorded as well as the time of the last dose of either study drug (remimazolam or fentanyl).
  13. Patient will be gently shaken and asked to open their eyes immediately after surgery stop. This will be repeated every 1 minute until patient is able to comply. Time of eye opening will be recorded.
  14. Patient will remain seated and monitored until assessed and determined that they are fit for discharge. Assessment will occur every minute, and this time will be recorded (anesthesia stop). Fitness for discharge will include modified Aldrete score ≥9, controlled pain, minimal/no PONV).
  15. If needed for rescue due to failed/insufficient sedation, or if the procedure extends beyond the 30 minute allowance for the study drugs, propofol and/or midazolam will be used to facilitate safe completion of the planned surgical procedure as per usual. Ondansetron (0.1 mg/kg up to 4 mg total) will be used for PONV rescue if the patient experiences nausea and/or vomiting postoperatively prior to discharge as per usual. All drugs listed here are considered standard of care for dental sedation procedures. If rescue drugs are administered, the use of the rescue drug will be documented in the study procedures. The subjects will be withdrawn from the study at the point of rescue drug administration and no additional study procedures will be followed or recorded from this point forward.
  16. Prior to discharge home, the patient will be asked to complete the Patient Satisfaction Survey which consists of 5 questions answered using a 5-point Likert scale. This survey will be repeated within 24 hours on postoperative day 1 via telephone.
  17. The operating surgeon will complete a satisfaction survey using a 5-point Likert scale after the procedure is complete.
  18. Patients will be asked to follow up with their operating surgeon at the same clinic as per usual. Instructions will be given to the patient and escort prior to discharge detailing contact information in case any adverse events/reactions occur afterwards per usual. All other postoperative instructions and analgesic prescriptions will follow established departmental standards of care.
Being tested
fentanyl and Remimazolam
Keywords
Extraction, sedation, fentanyl, Remimazolam, dental

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • fentanyl and RemimazolamDrug

    This is the first dental study that will combine these two sedation drugs

Study groups in NCT06793358
Study groupRoleWhat they receive
Fentanyl and Remimazolam combinedExperimentalRemimazolam has received FDA approval for procedural sedation in adults undergoing procedures lasting 30 minutes or less. While remimazolam has been used in studies for procedural sedation outside of dentistry and oral surgery, there are no dental studies from the US that have assessed its safe and effect use along with fentanyl as described in the package insert. This single-armed study will assess the efficacy of FDA-approved remimazolam combined with fentanyl for procedural sedation (defined as MOAA/S score ≥2) in healthy (ASA 1 and 2) adults undergoing dental extractions expected to last 30 minutes or less. To date, there are no studies in the US that have assessed the effectiveness of remimazolam and fentanyl for procedural sedation for dental treatment, including extractions, so this is the first study of its kind.
Receives: Drug: fentanyl and Remimazolam

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Outcome Measure for IV Sedation for completion of Surgery using successful extraction of teeth (1)

    Successful extraction of the indicated teeth (assessed at end of surgery)

    Measured: 30 minutes extraction period at the end of surgery

  2. Primary Outcome Measure for IV Sedation for completion of Surgery (2) using MOAA/s scores (

    Maximum MOAA/S scores (Modified Observer's Assessment of Alertness and Sedation Score) of 2-4 during the procedure (score rande of 0 to 6 with 0 meaning no response to stimulus (assessed every 5 minutes)

    Measured: 30 minutes extraction period at the end of surgery

  3. Primary Outcome Measure for IV Sedation for completion of Surgery determined by no need for rescue medications (3)

    No need for rescue medications (propofol, flumazenil, naloxone).

    Measured: 30 minutes extraction period at the end of surgery

Secondary outcomes (1)
  1. Secondary Outcome Measure related to timing related to anesthesia length, surgery, eye opening and discharge

    Time associated with anesthesia length, surgery length,eye opening, discharge

    Measured: 30 minutes extraction period at the end of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2025
  2. Study start31 Jul 2025
  3. Primary completion27 Feb 2026
  4. Study completion27 Feb 2026

Why it stopped: No one was enrolled to date and the sponsor requested the study be withdrawn

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06793358
Sponsor's protocol ID
22891
Status last verified
Feb 2026
First submitted
16 Dec 2024
Last updated
3 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing fentanyl and Remimazolam in people with Dental Extraction, run by Indiana University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Outcome Measure for IV Sedation for completion of Surgery using successful extraction of teeth (1) (time frame: 30 minutes extraction period at the end of surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in